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Neonatal sepsis remains a major health issue worldwide, especially for low-birth
weight and premature infants, with a high risk of death and devastating sequelae.
Apart from antibiotics and supportive care, there is an unmet need for adjunctive
treatments to improve the outcomes of neonatal sepsis. Strong and long-standing
research on adult patients has shown that vascular endothelium is a key player in
the pathophysiology of sepsis and sepsis-associated organ failure, through a direct
interaction with pathogens, leukocytes, platelets, and the effect of soluble circulating
mediators, in part produced by endothelial cells themselves. Despite abundant evidence
that the neonatal immune response to sepsis is distinct from that of adults, comparable
knowledge on neonatal vascular endothelium is much more limited. Neonatal endothelial
cells express lower amounts of adhesion molecules compared to adult ones, and
present a reduced capacity to neutralize reactive oxygen species. Conversely, available
evidence on biomarkers of endothelial damage in neonates is not as robust as in adult
patients, and endothelium-targeted therapeutic opportunities for neonatal sepsis are
almost unexplored. Here, we summarize current knowledge on the structure of neonatal
vascular endothelium, its interactions with neonatal immune system and possible
endothelium-targeted diagnostic and therapeutic tools for neonatal sepsis. Furthermore,
we outline areas of basic and translational research worthy of further study, to shed light
on the role of vascular endothelium in the context of neonatal sepsis.
Keywords: neonatal infection, neonatal inflammation, glycocalyx, sepsis therapy, sepsis diagnosis, sepsis
biomarkers, newborn
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INTRODUCTION
Our knowledge of the anatomy and function of the immune
system in early life have greatly improved over the past few
decades. Neonatal immune responses to exogenous stimuli, like
pathogens and vaccines, presents distinct features compared to
adults, including:
a) A clear prevalence of innate vs. adaptive immune
mechanisms, even in cells classically considered “adaptive”
such as CD8+ T cells (1–3);
b) Diminished chemotaxis and phagocytic activity of
polymorphonuclear granulocytes (PMNs) and of monocytes
under stress conditions in vitro (Marodi 1980, 135 Eur
J Pediatr; Fox 2005 Cytokine; Arinola 2003 Afr J Med
Med Sci);
c) Diminished pro-inflammatory activity and T-helper 1
(Th1) polarization of antigen-presenting cells (APCs)
and lymphocytes, characterized by weak production of
interleukin (IL)-12p70, interferon (IFN)-γ and tumor
necrosis factor (TNF)-α in response to most vaccines and
pattern recognition receptors (PRRs) agonists, with the
partial exception of Bacille Calmette Gurerin (BCG) vaccine
and Toll-like receptor (TLR)-8 agonists (4–6);
d) Relatively high production of IL-17 and IL-23, hallmarks of
Th2-Th17 polarization of immune response, of IL-6 and IL-
10 (especially in preterm neonates), the latter a powerful
anti-inflammatory cytokine (7).
e) The influence of distinctive immunomodulatory
blood components, such as maternal antibodies, high
concentrations of adenosine, and reduced concentrations of
complement (4, 8).
Despite such progress, we still lack a comprehensive grasp of the
complex immune mechanisms regulating the pathophysiology of
neonatal sepsis.
Basic and translational research has shed some light on
features of neonatal immune response to sepsis. Nonetheless,
the literature is incomplete and sometimes apparently
contradictory. For example, the aforementioned lower
production of proinflammatory cytokines is highly context-
dependent: while pro-inflammatory/Th1-polarizing responses
by isolated neonatal APCs in vitro to pure PRR agonists
are frequently impaired, responses by the same cells to live
microbes (akin to the context of sepsis) may be robust (9, 10).
Furthermore, in vivo, clinical and experimental evidences
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a
thrombospondin type 1 motif, member 13; APACHE-II, Acute Physiology and
Chronic Health Disease Classification System II; CD, cluster of differentiation;
CFU, colony-forming unit; CXCL-8, C-X-C motif chemokine ligand 8; Flt-1,
FLT1, fms-related tyrosine kinase 1; G-CSF, granulocyte colony-stimulating factor;
GM-CSF, granulocyte-macrophage colony-stimulating factor; MHC-II, major
histocompatibility complex - class II; MIP-1β, macrophage inflammatory protein
1β. NOD-like receptor, nucleotide-binding oligomerization domain-like receptors;
PAI-1, plasminogen activator inhibitor-1; RANTES, Regulated upon Activation,
Normal T cell Expressed, and Secreted (chemokine); RIG-I-like receptor, retinoic
acid-inducible gene I-like receptors; SOFA, Sequential Organ Failure Assessment;
Tie, tyrosine kinase with immunoglobulin-like and EGF-like domains; VCAM,
vascular cell adhesion molecule.
suggest an exaggerate susceptibility to systemic inflammatory
response during the acute phase of sepsis, by both neonatal
experimental animal models and human patients, especially if
born preterm (11, 12).
This incomplete understanding of neonatal immune
pathophysiology has also impaired the development of new
therapeutic agents: sepsis therapy in neonates (and similarly
in adults) has not evolved significantly from antibiotics, fluid
resuscitation and vasopressors. Indeed, new preventive and
therapeutic strategies are needed to limit the burden of neonatal
sepsis (13).
In adult patients, the vascular endothelium (VE) has received
substantial attention by scientists and clinicians, as there is
increasing evidence on its role in the pathophysiology of sepsis
and sepsis-associated organ damage (14, 15).
VE interacts with, and responds to leukocytes, soluble
mediators, pathogen-associated molecular patterns (PAMPs) and
damage-associated molecular patterns (DAMPs) involved in the
pathogenesis of sepsis. It has a major role in the regulation
of vascular permeability (16), in the modulation of local
inflammatory responses (17) and, ultimately, in the development
and progression of sepsis-associated multi-organ failure (15, 18,
19). In comparison, the role of VE in the pathophysiology of
neonatal sepsis has been marginally investigated.
As summarized in Figure 1, we recap in this review
the current evidence supporting a direct interplay between
the immune system and VE during neonatal sepsis. We
emphasize which research tools have been used, and others
that could be used in the future to monitor endothelial
function in neonates during health and sepsis, and we
discuss potential immune-therapeutic interventions targeting the
VE that deserve age-specific investigation in the context of
neonatal sepsis.
NEONATAL IMMUNE RESPONSE TO
SEPSIS
According to the most recent definition for adult patients,
sepsis is a life-threatening organ dysfunction caused by a
dysregulated host response to infection (20). It is by now well-
established that adult sepsis criteria do not sensitively detect
neonatal sepsis, reflecting a distinct age-specific host-pathogen
interactions (21). Of note, there is currently no consensus
definition of neonatal sepsis (22). Most datasets report an overall
incidence of culture-positive early-onset neonatal sepsis (EOS)
of ∼ 0.98/1,000 live births, rising up to 1.4–4 cases/1,000 live
births in very low birth weight infants (VLBWI), the more
susceptible population (23, 24). Late-onset sepsis (LOS), has a
more variable incidence, up to 30% in extremely low-birth weight
infants (ELBWI) (25, 26).
Mortality rate is the highest for sepsis caused by Gram-
negative bacteria (26) and, interestingly, more than half (50–
57%) of non-survivor neonates die within the first 3 days of
sepsis onset (27). This data, together with evidence linking
mortality during the acute phase of neonatal sepsis to a
dysregulated pro-inflammatory response (28, 29), highlight the
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FIGURE 1 | Structure of neonatal vascular endothelium (VE) and interactions with neonatal immune system, at steady state and during sepsis. Red boxes indicate
known features of neonatal VE and immune system compared to adults. Gray boxes identify areas for further research. Green boxes identify new experimental
endothelium-targeted therapeutic opportunities for neonatal sepsis. NETs, neutrophils extracellular traps; NF-kB, nuclear factor kappa-B; ERK ½, extracellular
signal-regulated kinases 1 and 2; β-cat, beta-catenin; SOD-2, superoxide dismutase 2; TRIF, TIR-domain-containing adapter-inducing interferon-β; IL, interleukin;
Ang1-2, Angiopoietin 1-2; Tie2, TEK receptor tyrosine kinase; cAMP, cyclic-adenosine monophosphate; AMP, adenosine monophosphate.
importance of the acute phase in shaping the outcomes of
neonatal sepsis.
Interestingly, mortality rate in septic adult patients during the
acute phase has been significantly reduced over the past 20 years,
andmost deaths now occur weeks to years after the septic episode
(30). This seems due to long lasting immunological, metabolic,
and biochemical aberrations gathered under the definition of
“sepsis-induced immunosuppression” (SII) or, with a slightly
different pathophysiological shade, “persistent inflammation,
immunosuppression and catabolism syndrome” (PICS) (31, 32).
Data on a possible SII or PICS in septic neonates, akin to that
of adult patients, is still limited (33), but this epidemiological
difference highlights the importance of age-specific investigation
of the pathogenesis of neonatal sepsis.
Interaction Between Neonatal Immune
Cells and Invading Pathogens
In case of culture-positive sepsis, the first pivotal event is
the systemic diffusion of the invading pathogen from the site
of infection, due to a defective containment by a localized
and limited immune response. Inability to contain and clear
pathogens locally is one of the most characterized features
of innate immune response in neonate. Compared to adults,
neonates present a reduced recruitment of PMNs to the site of
local infection (34, 35), lower MHC-II expression by antigen-
presenting cells (36), lower phagocytic activity by mononuclear
cells (37, 38), diminished intracellular killing by reactive oxygen
species (ROS) (35), and reduced extracellular formation of
neutrophil extracellular traps (NETs), also favored by soluble
NET-inhibitor compounds (39). These attributes are even more
prominent in preterm neonates (40–44).
Once bacterial dissemination in the bloodstream takes place,
human neonates display on average much higher pathogen loads
per ml of blood compared to adults, up to 1,000 CFU/ml
vs. 50 CFU/ml (45, 46). This observation has been replicated
in animal models of neonatal sepsis in vivo (47). As recently
hypothesized, both the impaired immune response at the
infection site and the higher bacterial load in the bloodstream of
septic neonates may be the consequence of a “microbe-tolerant”
strategy, actively carried out by the neonatal immune system
(48). Evolutionary, a “disease-tolerant” strategy reduces energy
consumption compared to a “disease-resistant” phenotype, is
coherent with lower energy stores of neonates, avoids the shift to
a catabolic state that would impair growth, and is advantageous
for establishing the symbioticmicrobiota. Furthermore, tolerance
toward microorganisms is in line with the prevalence of T-
regulatory and anti-inflammatory function demonstrated in the
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fetus (49) and the neonate (50). Nonetheless, considered the high
morbidity and mortality rates of neonatal sepsis, further and
stronger evidences need to be acquired before the concept of an
“evolutionary favorable” tolerance strategy could be applied in
this context.
The Inflammatory Response in Neonatal
Sepsis
In neonates as well as in adults, the propagation of invading
pathogens to the blood stream is followed by a systemic
inflammatory response (19). As the contradictory data from
several studies seem to indicate, measuring and deciphering
systemic inflammation during neonatal sepsis is not trivial.
First, several studies in vitro showed that isolated neonatal
immune cells, such as monocytes or dendritic cells, produce
lower amounts of TNF, IL-1β, and IFN-γ compared to adult
cells when stimulated with different PRRs agonists or with
microorganisms, but equal or even higher amounts of Th17-
promoting cytokines (IL-23, IL-6) and IL-10 (7, 51–57). These
results were also replicated with human whole blood ex vivo (58).
In animal models of polymicrobial sepsis, neonates tend to show
lower absolute plasma concentrations of TNF-α, IL-1α/β, IL-12,
GM-CSF, CCL5 (RANTES), macrophage inflammatory protein
(MIP)-1β and IFN-γ as compared to adults, when challenged
with an equally-lethal dose of “cecal slurry” (59).
Conversely, some evidences support the concept of a strong
systemic inflammatory response in neonates. First, IL-18 was
found to be higher in both healthy and septic neonates compared
to adults, and strongly correlated to morbidity and mortality in
neonatal sepsis (60, 61). Second, other cytokines such as IL-6
and IL-10, the latter being an important soluble mediator for
resolution of inflammation (62), seem to be produced by septic
neonates in comparable or sometimes higher amounts compared
to adult patients (63, 64), and several studies correlated the
adverse outcomes of sepsis (i.e., septic shock or non survival) with
higher concentrations of IL-10 and higher IL-10/TNF-α ratio, in
neonates as well as in adults (33, 65, 66). Third, higher mortality
rates and increased plasma levels of TNF, IL-6 and macrophage
chemotactic protein (MCP)-1 have been reported in newborn
mice challenged with a really equal dose (per gram of weight)
of pure bacterial lipopolysaccharide (LPS), a TLR4 agonist, or
poly(I:C), a TLR3 agonist, compared to adult mice (11). Overall,
clinical and experimental studies highlight the complexity of
systemic inflammatory response in neonates: notwithstanding
neonatal cells show a distinct and often impaired production
of cytokines and chemokines (especially for some classical pro-
inflammatory cytokines) compared to adult cells, the impaired
ability in vivo to contain locally the invading pathogen(s) leads to
high bacterial loads in the blood stream and distant organs. This,
ultimately, fuels an intense, systemic, acute pro-inflammatory
response that seems responsible for high morbidity andmortality
in the acute phase of sepsis (67).
An almost missing piece of this puzzle, at least for what
concerns neonatal sepsis, is the role of VE during the systemic
inflammatory response boosted by invading pathogens. VE
lies at the crossroad between invading pathogen, inflammatory
response, coagulation system and organ damage (68, 69), all key
components in the pathogenesis of sepsis, in adults as well as
in neonates.
STRUCTURE OF THE VE IN ADULTS AND
NEONATES
The endothelial wall structure, in neonates as well as in adults,
is composed by a single-layer of endothelial cells (ECs), sealed
by intercellular junctions and covered by the extra-cellular, intra-
luminal structure glycocalyx.
Structure of the Endothelial Cells Layer
Cell-to-cell junctions in the VE comprise VE-cadherins, forming
adherent junctions (AJs), and tight junctions (TJs). VE-cadherins
are surface adhesion glycoproteins that form a “zipper-like”
structure at the base of ECs and are connected to the underlying
components of the cytoskeleton, like β-catenin (70). TJs, instead,
occupy the apical part of intercellular space and predominantly
consist of individual protein filaments of occludin and claudin,
that form the so-called “zonulae occludentes.”
Altogether, VE-cadherins and TJs seal the intercellular space
between ECs and regulate the paracellular flow of fluids and
solutes that occurs passively as the result of oncotic and
hydrostatic pressures at both sides of endothelial layer according
to the Starling’s principle. The transcellular pathway of molecules
through ECs, instead, is an active process that requires either cell
fenestration or a transport system through intracellular vesicles.
Besides VE-cadherins and TJs, other adhesion proteins
contribute to the integrity of vascular endothelial barrier, as
intercellular adhesion molecule-1 (ICAM-1, CD54), ICAM-2,
platelet endothelial cell adhesion molecule (PECAM)-1 (CD31),
CD34, and endoglin (70). On the apical surface, facing the
vascular lumen, ECs express transmembrane glycoproteins that
mediate the first contact and rolling of leukocytes, mainly P-
selectin and E-selectin, and those mediating the subsequent
firm adhesion and extravasation processes (immunoglobulin-
like molecules as ICAM-1, ICAM-2 PECAM-1, and VCAM-1,
interacting with integrins expressed on leukocytes). Leukocytes-
endothelium adhesion molecules have been subject of an
excellent review (71).
Several aspects of endothelium structure and physiology in
neonates, especially if born preterm, are different from adults,
and may play a significant role in the pathogenesis of neonatal
sepsis (Figure 1).
ECs isolated from fetuses up to 22 weeks of gestational age
do not express P-selectin, and intracellular storage of P-selectin
in preterm neonates is less than half that of term neonates, at
steady state; this, in turn, contributes to the observed defect
in rolling, adhesion and crawling of neonatal neutrophils (72).
Similarly defective up-regulation of inducible E-selectin, ICAM-
1 and VCAM-1 upon LPS stimulation of human umbilical vein
ECs (HUVECs) from preterm neonates has been noted (73, 74).
Of note, it has also been shown that endothelial selectins, E-
selectin and P-selectin, are expressed at least partially during
fetal development in humans: in particular, P-selectin seems
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expressed at adult levels since 11 weeks of gestation while,
interestingly, E-selectin reaches adult levels on ECs around 32
weeks (75). Overall, endothelium-mediated adhesion and rolling
of neutrophils, either at steady state or during an inflammatory
process, seem to be impaired in neonates as compared to adults,
and among neonates the severity of this impairment seems
gestational age-dependent.
Furthermore, differences between adults and neonates exist
also for what concerns endothelium metabolism: for example,
HUVECs, as compared to human microvascular ECs (HMVEC)
derived from adults, express higher levels of hydrogen peroxide
and lower amounts of ROS-neutralizing enzymes, such as
superoxide dismutase 2 (SOD2) and catalase, in response to
hyperglycemia (76): this study suggests a potential epigenetic-
mediated difference between neonatal and adult ECs in the
capacity to neutralize ROS. Considering that both ROS and
reactive nitrogen species (RNS) facilitate endothelial dysfunction,
increase cell wall permeability and induce a pro-coagulant state,
especially in non-physiological conditions of stress like sepsis,
it is conceivable that reduced neutralizing capacity of ROS and
RNS by neonatal ECs might play a role in driving endothelial
metabolic dysfunction during a septic state (77).
Finally, two concepts regarding the investigation of
endothelial cells in vitro need to be taken in consideration
and should prompt more age-specific research. First, even in
the context of adult sepsis, most researchers use HUVECs as a
model because of their availability and practicality. If we accept
that differences between neonatal and adult endothelium exist,
most of the results obtained with such model might more closely
reflect neonatal rather than adult physiology. Second, in vitro
models to investigate neonatal VE should carefully replicate all
age-specific microphysiological conditions, such as the quality
and origin of plasma, the basement substrate and the interacting
immune cells, in order to more accurately model age-specific
biology that is relevant in vivo, thereby enhancing translational
research (78).
The Glycocalyx
Above the surface of ECs, and directly in contact with blood,
lies the glycocalyx, a 0.1–3µm thick multi-layer structure of
glycoproteins whose functions are to hide most of the adhesion
molecules expressed by ECs, maintain the selective permeability
of endothelial barrier, inhibit blood coagulation, and serve as a
mechanotransducer between blood flow and the endothelial cell
wall (79).
The glycocalyx is a dense network composed by two families
of protein cores anchored to the EC wall, syndecans and
glypicans, a few protein cores not anchored to ECs, such as
perlecan and versian, and several secreted glycosaminoglycans
(GAGs) attached to the protein cores, like heparan sulfate
and hyaluronan (80). Glycocalyx is negatively charged and its
structure does not allow the passage of proteins larger than 70
kDa. It repels most plasma proteins, including immunoglobulins,
with the exception of albumin, that with a molecular weight
of 67 kDa and its amphoteric nature can bind and cross, at
least partially, the surface of glycocalyx: the net effect of this
interaction is that, under physiological conditions, albumin itself
contributes to tighten the glycoprotein network and remains
trapped on the glycocalyx, to the point that only 5% of body
albumin normally leaks into the interstitial space (81). Thus,
the glycocalyx significantly contributes to maintain the oncotic
pressure gradient across the endothelial barrier.
Despite the growing body of literature on adult patients
and experimental models on adult animals, the structure and
function of glycocalyx in neonates have only been marginally
explored. Over 40 years ago, it was shown that neonatal VE
has a permeability to albumin that is 3 to 4 times higher than
that in adults (82) and, in experimental animal models, that
the fetus has a protein reflection coefficient at the endothelial
interface, an index of resistance to the extravasation of proteins,
that is just 70 to 90% of the adult one (83). In addition, few
authors explored the shedding of glycocalyx components into
the circulation during systemic inflammation states, such as
sepsis, as summarized afterwards in this review. The glycocalyx
structure has been studied in the context of necrotizing
enterocolitis, with focus limited to the glycocalyx coating the
luminal side of enterocytes (84). Studies directly investigating
the biological structure of vascular endothelial glycocalyx in
early life, either in the fetus or the preterm neonate, are
still lacking.
INTERPLAY BETWEEN IMMUNE SYSTEM
AND ENDOTHELIUM DURING NEONATAL
SEPSIS
It has long been recognized that both ECs and the glycocalyx
have an active role in inflammatory processes, and a deep
functional connection with the immune system (85).
Furthermore, the endothelium has an active role in the
regulation of the coagulation process, which is another
fundamental epiphenomenon of systemic inflammation
and infections: thus, the triad (a) endothelium, (b)
immune response, and (c) coagulation cascade need
all be considered as a whole, at steady state as well as
during systemic inflammation.
Glycocalyx During Neonatal Sepsis
Due to its apical position, the glycocalyx encounters circulating
pathogens and blood solutes first. It has been shown that
the glycocalyx is degraded in the presence of several stimuli,
such as ROS, bacterial endotoxin (LPS), hyperglycemia,
hypovolemia or pro-inflammatory cytokines, especially TNF-
α and IL-1β (80). This process is mediated by either direct
damage to structural components or by the cleaving action
of proteolytic and glycolytic enzymes, such as heparanase-
I and metalloproteinases (MMPs) (86). Heparanase-I, in
particular, is pre-stored in cytoplasmic granules of ECs and
can be released upon stimulation of ECs by either cytokines
or endotoxin.
The disruption of glycocalyx has four major consequences on
VE (Figure 2):
1) An increased permeability of endothelium to proteins,
including albumin, and consequently to free water;
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FIGURE 2 | Consequences of the degradation of endothelial glycocalyx. (1) increased permeability to proteins, including albumin, and to free water; (2) exposure of
adhesion molecules on the surface of ECs; (3) increased diameter of microscopic vessels; (4) loss of sheer stress monitoring and signaling from the glycocalyx
structure to the ECs and smooth muscle cells. TJs, tight junctions; β-cat, beta-catenin; NO, nitric oxide; NOS, nitric oxide synthase; L-arg, L-arginine.
2) The exposure of adhesion molecules on the surface of
ECs, that favor the trapping and activation of immune
cells: activated neutrophils, in particular, can also provide
a determinant contribution to diffuse microvascular
thrombosis, as outlined below;
3) The increased diameter of microscopic vessels in those
areas where glycocalyx is more damaged, leading to non-
homogeneous perfusion of capillary beds;
4) The loss of sheer stress monitoring and signaling from the
glycocalyx structure to the ECs, that contributes to the loss of
vascular reactivity.
Robust evidence concerning the role of glycocalyx degradation
in shaping the pathophysiology of neonatal sepsis is still
lacking; nonetheless, its importance can be reasonably
presumed when considering that the clinical course of severe
neonatal sepsis and septic shock is characterized by systemic
hypotension, hypoalbuminemia, diffuse edema, disseminated
intravascular coagulation and, ultimately, multi-organ damage
and failure (67, 87). Hypoalbuminemia and hypotension
during neonatal sepsis are frequently tackled with albumin
infusion, in the attempt to raise intravascular oncotic pressure
despite the absence of scientific evidence, or evidence-based
therapeutic individualization (88). In few septic neonates,
indeed, albumin may not elicit the desired effect but, instead,
worsen the water shift toward the extravascular space (89).
The role of endothelial glycocalyx in these cases has yet to
be explored.
Finally, circulating heparan sulfate, an end product of
damaged glycocalyx, can induce a strong pro-inflammatory
response and mitochondrial dysfunction in cardiomyocytes
during experimental sepsis (90, 91). Myocardial dysfunction
is one of the key mediators of systemic hypotension and
organ hypoperfusion in the context of neonatal septic shock
(92). Given the influence of glycocalyx end-products on
cardiomyocytes, it will be important to characterize how these
circulating molecules affect the function of myocardium during
neonatal sepsis.
Endothelial Cells in Neonatal Sepsis
ECs are directly involved in the pathophysiology of sepsis and can
play several immune functions (85). ECs express a wide range of
PRRs, including TLRs, RIG-I-like and NOD-like receptors (93),
that directly interact with different PAMPs in the bloodstream,
such as streptococcal toxins (94).
HUVECs and adult-derived ECs, like HMVECs, seem to
express comparable amounts of TLRs, with high density of TLR1,
3 and 4 and the virtual absence of TLR7 and TLR8 (95). As
in APCs, the activation of PRRs on ECs induces production
of cytokines and chemokines. In septic neonates, high plasma
concentrations of IL-1β, IL-6, CXCL8 (IL-8), TNFα, and G-
CSF are not mirrored by the elevation in the corresponding
mRNA isolated from leukocytes, suggesting that cells other
than leukocytes may contribute to the production of those pro-
inflammatory mediators (96). Indeed, PAMPs, such as LPS,
induce a strong upregulation of pro-inflammatory cytokines in
ECs (85). Conversely, the effect of PAMPs on ECs is amplified
by circulating pro-inflammatory cytokines that create a positive-
feedback loop by inducing the upregulation of surface PRRs
themselves (95).
Neonatal sepsis is characterized by high plasma levels of IL-
6, CXCL8 (KC in murine models) and IL-18 (28, 60, 67, 97).
Both human and experimental animal models suggest, that
substantial amounts of these pro-inflammatory cytokines may
be produced by activated ECs in the context of sepsis. For
example, both IL-18 and IL-18R are expressed by adult atheroma-
associated ECs (98), while IL-6 and CXCL8 are produced in
significant amounts by ECs stimulated by LPS, TLR2 agonists
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or other circulating pro-inflammatory cytokines like IL-1 (99–
101). Further characterization of endothelium-derived pro-
inflammatory cytokines in neonatal sepsis, as well as the effects
of therapies targeting cytokine-induced endothelial activation
during neonatal sepsis, is required.
The local effect of endothelium-derived cytokines is to
create a gradient to guide neutrophils and monocytes to
peripheral tissues. This effect on inflamed vasculature seems
to be attenuated in septic neonates compared to adults and
in preterm neonates compared to term ones: in vitro studies
(42, 102) have shown how chemotaxis and transmigration of
PMNs is impaired in septic neonates, because of the reduced
expression of adhesion molecules (mainly E-selectin, P-selectin,
and ICAM-1) on ECs and their respective ligands on leukocytes
(74): this, in turn, may be due to depressed TNF-α production
during systemic inflammation, as shown in experimental models
of neonatal pulmonary infection (103). Interestingly, these
data on inflammatory states were recently complemented by
the observation that neonates present a significant endothelial
activation at the steady-state (104). This seems supported by
monocyte-derived TNF-α, and promotes leukocyte trafficking
through peripheral tissues during the physiological neonatal
period. Thus, overall, current evidences support the concept of
a higher baseline activation of neonatal endothelium, possibly
cytokine-mediated, followed by an impaired up-regulation of key
functions (expression of adhesion molecules) during systemic
inflammation (Figure 1).
Damaged or activated VE greatly supports the establishment
of a prothrombotic environment, in order to contain the damage
locally and to avoid the spread of the harmful stimulus through
systemic circulation (105). In adults, disseminated intravascular
coagulation is a major contributor to the establishment and
progression of multi-organ failure (MOF) during severe sepsis
and septic shock, together with mitochondrial dysfunction,
direct cytotoxicity of bacterial toxins and cytokine-induced
apoptosis (106). MOF is also typical of severe neonatal sepsis
(67), and activated/damaged VE may play a significant role
in its pathogenesis. In addition to promoting adhesion of
leukocytes through the exposure of adhesionmolecules, activated
endothelia release large amounts of vonWillebrand factor (VWF)
promoting aggregation of platelets, granulocytes and monocytes.
Granulocytes, in turn, release NETs, while activated monocytes
express Tissue Factor that supports blood coagulation through
fibrin formation.
The active interplay between damaged/inflamed endothelium,
platelets, activated granulocytes, NETs and monocytes has been
termed “immunothrombosis,” a concept that has only been
recently demonstrated in vivo (107). The biological benefits
(e.g., reduced diffusion of circulating pathogens to tissues and
organs, reduced metabolic rate and oxygen consumption due
to diminished perfusion) and harms (e.g., ischemic damage,
shift toward anaerobic metabolism, reduced influx of immune
cells) of immunothrombosis during sepsis have been the subject
of a detailed review (108). These functions have been partially
explored in children (109, 110). To our knowledge, the biology
and systemic consequences of immunothrombosis, as well as
the role of neonatal VE in this process, have not yet been
investigated in the context of neonatal sepsis. VE, platelets and
leukocytes form a triad that cooperate in the establishment
and progression of MOF during severe neonatal sepsis. In this
context, immunothrombosis deserves a focused research effort to
enlighten the pathogenesis and development of new therapeutics
for neonatal sepsis.
HOW TO INVESTIGATE ENDOTHELIUM
AND GLYCOCALYX DURING NEONATAL
SEPSIS
Monitoring the structure and functional integrity of the VE has
already been regarded, at least in adult patients, as a fundamental
component of the patient’s evaluation during critical illness such
as sepsis (111).
The most commonly evaluated function of VE in the context
of neonatal sepsis is vasomotor regulation: albeit indirectly, the
ability of endothelium to regulate vascular tone is currently
assessed by visual inspection of skin color, evaluation of capillary
refill (112), perfusion index (113) and less frequently, near-
infrared spectroscopy (NIRS) of tissues (114). Furthermore,
blood lactate is routinely evaluated in adult and neonatal sepsis
as a marker of microcirculatory function and oxygen extraction
by peripheral tissues (67, 115). All of the above are indirect
and approximate methods, whose correlation with the real-time
status of endothelial barrier or the integrity of glycocalyx is
difficult to establish.
In the clinical context and experimental settings, two
methodologies are currently gaining attention from physicians
and scientists dealing with sepsis or septic shock in adult
patients and, with some adaptation, could be applied in the
context of neonatal sepsis: (1) imaging techniques, such as
intravital microscopy, and (2) the quantification of biomarkers
of endothelial damage.
Intravital Imaging
Before 1990, intravital microscopy was cumbersome and
confined to experimental research laboratories providing little to
no possibilities to translate observations and methodologies to
the patient’s bedside. Over the last 30 years, hand-held, intravital
microscopes became more portable and easy-to-use (15).
Three generations of devices based on different imaging
technologies were subsequently introduced: orthogonally
polarized spectral (OPS), sidestream dark-field (SDF) and
incident dark-field (IDF) microscopes (116). Currently, only
SDF and IDF imaging techniques are applied routinely to
bedsides, with a growing body of literature about their utility in
patients with sepsis and septic shock.
Leading scientists in the field, like Ince and co-workers, have
demonstrated that intravital microscopy is able to describe the
status of microcirculation both qualitatively and quantitatively
during critical illness such as sepsis, and that it can effectively
predict organ dysfunction and mortality (117, 118). Moreover,
intravital imaging can provide a direct evaluation of tissue
perfusion before and after therapeutic interventions, in adult and
neonates with septic shock. In this context, it’s important to note
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that not all alterations of microvascular circulation are due to
endothelial damage: indeed, significant contributions can come
from immunothrombosis, reduced red blood cells deformability
and altered vascular tone (119, 120). Thus, some authors have
tried to specifically identify features of endothelial dysfunction
and activation bymeans of intravital microscopy (121). Nieudorp
and coll. had previously shown that it is possible to derive
a measurement of glycocalyx thickness in vivo by measuring
the distance between flowing RBCs and the endothelial wall
(122), and in 2018, Uz and coll. validated a method to quantify
leukocytes adhesion to endothelium and rolling using space-time
diagrams derived from intravital microscopy (123).
The abovementioned technologies have been applied to
neonates (124–126), and it is anticipated that they may be
particularly useful in the context of neonatal sepsis and
septic shock.
Neonates, especially preterm, represent an optimal setting
for intravital microscopy, due to the reduced thickness of skin
and mucosae. Recently, it has been shown that buccal mucosa
may be the best site for evaluation of microvascular vessel
density in term neonates (127), while transcutaneous evaluation
seemed feasible and reproducible in healthy preterm infants (128,
129). It has also been demonstrated that persistent alterations
of microcirculation, as assessed by intravital microscopy, are
diagnostic of septic shock in children, with an area-under-
curve (AUC) of 0.956 (95% confidence interval 0.853–1.058),
and prognostic for survival (117). In preterm infants, daily
acquired images of cutaneous microcirculation were useful to
prove that functional small vessel density is reduced 1 day before
the appearance of clinical symptoms in culture-confirmed or
suspected late-onset sepsis (130). Similar results were obtained
on term neonates (131), demonstrating that the proportion of
microcirculation vessels with continuous flow is significantly
lower in infants with suspected infection compared to controls
(69 vs. 90%, p-value = 0.0003). While most of these results
are preliminary and obtained on small cohorts of children and
neonates, their correlation with real-time endothelial function,
e.g., levels of soluble markers, is not known: further studies on
the diagnostic and prognostic utility of intravital microscopy in
the context of neonatal sepsis, as well as its correlation with
endothelial dysfunction, are needed.
Biomarkers of Glycocalyx and Endothelium
Damage
The second way to study endothelial function during sepsis, in
neonates as in adults, is the quantification of soluble components
of endothelial wall and glycocalyx in plasma or urine (132). A
robust body of literature, including excellent reviews, exists about
the use of endothelial soluble biomarkers to evaluate the course of
sepsis in adult patients (133, 134). Five categories of biomarkers
are currently evaluated and proven useful in adult sepsis:
a) Proteases (e.g., MMPs);
b) Adhesion molecules (e.g., VCAM 1-2, ICAM-1-, E-selectin);
c) Coagulation factors (e.g., PAI-1, ADAMTS13, Von
Willebrand factor or Tissue Factor);
d) Glycocalyx end-products (e.g., syndecan, hyaluronan,
endocan) and cleaving enzymes (heparanase);
e) Endothelial growth factors and receptors (e.g., angiopoietin
(Ang)−1 and−2 with their receptors Tie-1 and−2, or VEGF-
1 with its cell-anchored or circulating decoy receptor Flt-1
and sFlt-1).
In adult patients, several of these biomarkers have been
correlated with endothelial damage/activation or with glycocalyx
degradation (frequently inter-correlated), and have shown good
association with severity scores, such as SOFA, and adverse
outcomes such as mortality (135, 136). This occurs in particular
when sustained elevation over time of multiple analytes is present
(137). Nevertheless, not a single biomarker has been proven to be
the “gold standard” for diagnosis or prognostic stratification of
adult septic patients.
In neonates, most published studies on soluble biomarkers
of endothelial damage during sepsis have focused on E-selectin,
sICAM-1 and sVCAM-1, aiming to demonstrate their early
diagnostic value (138). Results have been neither consistent
between studies nor straightforward to be interpreted: first,
reference levels for these biomarkers in early life are not
established and can be variable. For example, three different
studies (96, 139, 140) have shown that sICAM-1 plasma
levels tend to increase over the first month of life even in
healthy neonates, thus making it difficult to establish reference
ranges for sepsis. Second, enrollment criteria varied greatly,
frequently including both preterm and term neonates as well
as EOS and LOS. Third, definitions of sepsis diverge and are
not always directly comparable. Considering these limitations,
most authors have concluded that combinations of different
biomarkers of endothelial damage, associated with markers
of systemic inflammatory response such as C-reactive protein
(CRP) or IL-6, may improved sensitivity and specificity for
early diagnosis of neonatal sepsis, as compared to single
measurements (141–144). Following the results obtained on
adult patients, some groups extended their research to more
novel endothelial biomarkers during neonatal sepsis, mainly
components of degraded glycocalyx, endothelial growth factors
or components of tight junctions (TJs) that shed into circulation
upon endothelial damage. It has been shown that sTREM-1
(soluble triggering receptor expressed on myeloid cells-1) has a
AUC of 0.97 for the diagnosis of suspected or proven neonatal
sepsis, compared to 0.8 of Endocan and 0.96 of IL-6 (145).
Furthermore, the correlation between plasma levels of Ang-1,
Ang-2, sICAM-1, and sVCAM-1 and the occurrence of death
or bacteremia in term infants admitted for suspected sepsis has
been investigated. Ang-2 was shown to be higher at admission in
non-survivors, as well as Ang-2: Ang-1 ratio that also correlated
with bacteremia (146). Similar results were obtained by other
investigators (147).
The presence of TJs components in the blood as a marker
of endothelial damage has been investigated in several diseases
in adult as well as in pediatric patients, including pediatric
sepsis and neonatal necrotizing enterocolitis (148). Of note,
no study on neonatal sepsis has been published yet. Recently,
it has been demonstrated that plasma levels of occludin and
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zonula occludens (ZO)-1 are correlated with both APACHE II
score and SOFA score in septic adult patients, and that they
are useful to identify patients at risk for MOF (149). This study
highlights the interconnection between systemic inflammation,
endothelial damage and organ damage during severe sepsis. The
same investigational concept may be applied in the context of
neonatal sepsis, especially in those populations, like ELBWI, at
higher risk for severe course of sepsis, shock, MOF and death.
Overall, studies conducted on septic neonates compared
to those on adults show important limitations that restrict
their current utility but provide space for new research. For
example, the kinetics of several biomarkers over the course of
sepsis is not known for neonates, and the practical difficulty to
obtain serial blood samples in small patients complicates such
studies. Furthermore, most neonatal studies, with few exceptions,
are focused on the diagnostic value of biomarkers, without
prognostic correlation with clinical outcomes. A neonatal
adaptation of the SOFA score named “nSOFA” has been
recently proposed (150). The correlation between biomarkers of
endothelial dysfunction, a previously validated nSOFA score and
long-term outcomes of sepsis may improve the individualization
of therapy, and may help to clarify the molecular mechanisms
that increase the rates of long-term adverse outcomes in
septic neonates.
THERAPEUTIC OPPORTUNITIES
Besides antibiotics, fluid resuscitation and cardiovascular
support, we currently lack any other effective therapy to
counteract an invading pathogen and the self-induced damage
caused by an uncontrolled systemic inflammatory response in
septic neonates. A number of potentially immunomodulatory
drugs and strategies have been previously evaluated in adults as
well as in neonates, or are currently under investigation (13, 19).
Aside from pure immunotherapy, an increasing attention in
adult patients and in experimental models of sepsis is being
given to pharmacological interventions targeted to improve
the endothelial stability, or to act on the interplay between
endothelial barrier, glycocalyx, and immune cells (151–153)
(Figure 3). As mentioned previously, common features of severe
sepsis, both in neonates and adults, include reduced systemic
vascular resistance (SVR), interstitial edema, hypoalbuminemia,
hypotension, and MOF (19, 92). Endothelial damage has been
clearly implicated as contributing to each of these phenomena
in adult patients, and to a lesser extent in neonates. These
observations provide a rationale to investigate the effect of several
therapeutic agents, already in use or under investigation, on the
endothelial barrier of neonates in the context of neonatal sepsis.
Current Therapies That Affect Glycocalyx
Integrity
Some of the therapeutic agents already in use to treat sepsis
may impact the glycocalyx (152, 154). Hydrocortisone is used in
the context of neonatal refractory septic shock, to improve the
efficacy of vasomotor amines and counteract a possible relative
adrenal insufficiency, especially in very preterm neonates (67).
FIGURE 3 | Therapeutic agents that potentially improve or restore endothelial
function during neonatal sepsis. MMPs: metalloproteases. HMWH: high
molecular weight-hyaluronan. NAH, N-desulfated/re-N-acetylated heparin;
S1P, sphingosine-1-phosphate (S1P); Ang1-2, Angiopoietin 1-2; Tie2, TEK
receptor tyrosine kinase; PTX, pentoxifylline; cAMP, cyclic-adenosine
monophosphate; AMP, adenosine monophosphate; IMD40, intermedin
peptide 40 kD.
In experimental models of ischemia/reperfusion, intravenous
hydrocortisone reduced the shedding of syndecan-1, heparan
sulfate, and hyaluronan, limiting the formation of extravascular
edema (155). We are not aware of any published studies
regarding the impact of steroids on the glycocalyx structure and
function during sepsis, in adult or newborn patients. Another
example of therapeutic intervention for sepsis that may affect
glycocalyx is volume expansion with intravenous fluids, either
crystalloids or colloids (in most septic newborns represented
by albumin). This is frequently the first intervention to correct
hypotension in presumed septic neonates, but some studies
suggest that excess intravascular volume increases the shedding
of glycocalyx, possibly through increased shear stress or the effect
atrial natriuretic peptide (ANP) (156, 157). Furthermore, if the
glycocalyx is disrupted, a high proportion of the infused fluid
flows toward the extracellular space, favoring the formation of
edema and prompting the infusion of supplementary fluids in the
attempt to maintain intravascular volume.
Interestingly, albumin seems to be a double edge sword in
this context: as a part of the protein-glycan network forming
the glycocalyx, its infusion may help restoring the integrity of a
damaged glycocalyx, an effect not shared by any other colloid,
such as synthetic ones (158). Albumin also carries sphingosine-
1-phosphate (S1P) to the endothelial surface, and it is known
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that S1P can favor glycocalyx recovery suppressing MMP activity
(159). Conversely, when the damage to glycocalyx is too severe,
even albumin flows out to the extracellular space, increasing the
extravascular oncotic pressure and driving a further net flow of
water out of the vascular lumen (160).
Hypoalbuminemia and interstitial edema are relatively
common in neonates with septic shock. Nonetheless, no
clinical or experimental study investigated the correlation
between albumin administration, albumin extravasation and
glycocalyx degradation in neonatal sepsis: more research
is needed to understand the effect of current therapies
on endothelial wall and glycocalyx in the context of
neonatal sepsis.
S1P, Heparanase Inhibition and Hyaluronan
As mentioned previously, S1P is a natural inhibitor of syndecan-
1 shedding through the inhibition of MMPs. In experimental
models of sepsis, administration of fingolimod, a S1P receptor
modulator, improved left ventricular systolic contractility (161).
This effect may be due to a reduced shedding of glycocalyx
components, similarly to what has been shown by other studies
(90). No comparable evidence exists for neonatal sepsis yet.
Heparanase is a glucuronidase responsible for degradation
of the glycocalyx network, and possibly mediating renal
and lung injury during sepsis, as demonstrated in animal
models (162). Heparin can inhibit heparanase activity and
protect from shedding of glycocalyx components, even during
inflammatory states such as sepsis (163). However, heparin
infusion is frequently impractical in septic neonates due to its
potent anticoagulant activity and high risk for hemorrhage. N-
desulfated re-N-acetylated heparin (NAH), a heparin analog
devoid of anticoagulant properties, prevented glycocalyx loss
and neutrophil adhesion to ECs caused by endotoxemia in an
animal model of sepsis, thereby reducing renal and pulmonary
injury (164). This effect was confirmed also when NAH was
administered hours after the onset of experimental sepsis, with
a time-course that reproduces real-life intervention in septic
patients, including neonates. Finally, the anti-inflammatory
effect of high-molecular-weight hyaluronan (HMWH), a high-
molecular-mass polysaccharide and component of glycocalyx,
has been studied in the context of sepsis-induced lung injury
(165). HMWH prevented monocyte and neutrophil infiltration
into the lungs and the expression of macrophage inflammatory
protein-2 mRNA.
Overall, these preliminary studies suggest that restoration
of glycocalyx integrity during sepsis may represent a novel
therapeutic strategy that deserves a translation into the neonatal
context. S1P, NAH and hyaluronan, may represent the most
promising agents worth of age-specific investigation.
The Ang1/2–Tie2 Axis
Angiopoietins are vascular growth factors that promote
neo-angiogenesis interacting with their tyrosine kinase
receptor, Tie2, expressed on ECs. Angiopoietin 1 and
angiopoietin 2 have opposing effects on Tie2: Ang1
promotes endothelial stability and cell survival, strengthens
adherens junctions through the inhibition of NF-kB and
downregulates the expression of ICAM-1 and VCAM-1,
inhibiting leukocyte adhesion. Conversely, Ang2 is released
during inflammatory states or hypoxia, in the “attempt” to
restore a steady state environment. It promotes disruption
of intercellular junctions that favor neoangiogenesis,
increases the surface expression of ICAM-1 and VCAM-
1, and increase paracellular permeability to fluids and
proteins (166, 167).
Over the past 10 years, the Ang1/2—Tie2 axis has been
targeted by new experimental therapies aiming to reduce
endothelial damage during sepsis or other models of
systemic inflammation. Recombinant Ang1 can increase
survival and reduce the development of lung edema during
systemic inflammation induced by LPS, in a murine model
(168). Recently, it was also demonstrated that clustering
of Ang2, induced by a monoclonal antibody, induces a
more Ang-1–like response of Tie2, tightening VE-cadherin,
reducing heparanase synthesis and reducing the expression
of adhesion molecules by ECs (169). Finally, in a murine
FIGURE 4 | Role of endothelial activation and dysfunction in shaping the pathophysiology of neonatal sepsis, the short term effect of systemic inflammation as well as,
at least theoretically, the correlation between neonatal sepsis and mid/long-term adverse outcomes. BPD, bronchopulmonary dysplasia; ROP, retinopathy of
prematurity; COPD, chronic obstructive pulmonary disease.
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model of sepsis, the block of a secondary receptor of
Ang2, β-1 integrin, with a monoclonal antibody enhanced
stabilization of junctions between ECs, reduced vascular
leak and contraction of ECs induced by LPS and reduced
mortality (170). As previously mentioned, at least two
studies reported high level of Ang2 and Ang2:Ang1 ratio
in septic neonates (146, 171). Overall, these studies suggest
a possible benefit of Tie2 regulation in neonatal sepsis and
prompt a translational approach to early life. Furthermore,
Ang1 in newborns is a critical mediator of hyperoxia-
induced lung injury (172) and retinopathy of prematurity
(173). Accordingly, strategies directed at investigating and
therapeutically regulating Ang2-Tie2 axis may have benefits
in early life beyond the improvement of sepsis outcomes,
and could potentially reduce neonatal sepsis-associated
chronic complications.
Pentoxifylline
Pentoxifylline (PTX), a phosphodiesterase inhibitor that
enhances cellular cAMP concentrations, reduces TLR-mediated
and inflammasome-mediated cytokine production by neonatal
immune cells, in vitro (174, 175) and also in vivo (176).
Furthermore, PTX has been shown to reduce mortality of
septic neonates in small-size studies, and is currently under
investigation in a large trial that may provide a definitive
answer on its clinical efficacy (177). Aside from the effects
on cytokine production (which may anyhow involve ECs),
PTX ameliorates endothelial function in different experimental
models of critical illness, specifically of sepsis. For example,
PTX inhibits adhesion and rolling of leukocytes on ECs (178),
supports the preservation of a physiological endothelium-
mediated vasodilation (179), and reduces the expression of
P-selectin and ICAM-1 on mesenteric microvessels (180).
Furthermore, PTX can reduce the activity of wingless integrated
MMTV (Wnt)/β-catenin pathway (181), involved in the
conservation of endothelial intercellular junctions. These studies
provide a rationale to further explore the action of PTX on
VE during neonatal sepsis, both in vitro, to gain knowledge
about the molecular mechanisms regulating its activity, and
in vivo, monitoring the endothelial status and function (e.g.,
the quantification of endothelial biomarkers) during therapy
with PTX.
Antithrombin and Intermedin
Very recently, the beneficial effect of two additional
molecules on endothelial integrity has been demonstrated
in experimental models of sepsis. Antithrombin infusion
reduced circulating levels of syndecan-1, hyaluronan and lactate
in a rat model of sepsis (182). Furthermore, antithrombin
inhibited leukocyte adhesion and attenuated the reduction
of blood flow through capillaries due to immunothrombosis,
highlighting once more how coagulation and endothelial
function are deeply interlaced in the context of sepsis.
Intermedin (IMD), a member of the calcitonin family,
and its peptide IMD40, alleviate the increase of vascular
leakage and protect the endothelium against the effect
of cytokine storm during experimental sepsis (183). The
administration of IMD peptide improved the survival of septic
mice, re-establishing the endothelial barrier and reducing
inflammatory responses.
CONCLUSIONS
VE has emerged as a fundamental sepsis mediator interposed
between the effect of the invading pathogens, the systemic
immune response of the host and the multi-organ damage
that ultimately leads to death. Furthermore, several long-term
consequences typical of prematurity, such as bronchopulmonary
dysplasia, retinopathy of prematurity and neurodevelopmental
impairment, have increased incidence in previously septic
neonates compared to those who never experienced sepsis.
The VE may mediate some of these long-term consequences
(Figure 4), but evidence supporting such a theory is limited.
Finally, an improved comprehension of leukocyte-endothelium
interactions in early life may enhance in vitro modeling of
the action of vaccines and immunomodulators, to improve
the efficacy of preventative strategies such as neonatal
immunization (78).
Despite the distinct nature of neonatal sepsis and its heavy
toll, basic and translational research on endothelial function at
early stages of life, in health and disease, lags substantially behind
its adult counterpart. Age-specific investigation of endothelial
structure, of the interactions between ECs, glycocalyx, pathogens
and immune cells, and of the effect of endothelial damage on
the course of neonatal sepsis, may define a key link between
sepsis and multi-organ damage. Cooperation between scientists
and neonatologists is fundamental to deepen the investigation of
molecular pathways and immunological mechanisms regulating
endothelial dysfunction during neonatal sepsis, and inform
new approaches to endothelium-targeted therapies that may
significantly improve short- and long-term outcomes.
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